Cargando…
Lipid chaperones and associated diseases: a group of chaperonopathies defining a new nosological entity with implications for medical research and practice
Fatty acid–binding proteins (FABPs) are lipid chaperones assisting in the trafficking of long-chain fatty acids with functions in various cell compartments, including oxidation, signaling, gene-transcription regulation, and storage. The various known FABP isoforms display distinctive tissue distribu...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591661/ https://www.ncbi.nlm.nih.gov/pubmed/32856199 http://dx.doi.org/10.1007/s12192-020-01153-6 |
_version_ | 1783601032191803392 |
---|---|
author | D’Anneo, Antonella Bavisotto, Celeste Caruso Gammazza, Antonella Marino Paladino, Letizia Carlisi, Daniela Cappello, Francesco de Macario, Everly Conway Macario, Alberto J. L. Lauricella, Marianna |
author_facet | D’Anneo, Antonella Bavisotto, Celeste Caruso Gammazza, Antonella Marino Paladino, Letizia Carlisi, Daniela Cappello, Francesco de Macario, Everly Conway Macario, Alberto J. L. Lauricella, Marianna |
author_sort | D’Anneo, Antonella |
collection | PubMed |
description | Fatty acid–binding proteins (FABPs) are lipid chaperones assisting in the trafficking of long-chain fatty acids with functions in various cell compartments, including oxidation, signaling, gene-transcription regulation, and storage. The various known FABP isoforms display distinctive tissue distribution, but some are active in more than one tissue. Quantitative and/or qualitative changes of FABPs are associated with pathological conditions. Increased circulating levels of FABPs are biomarkers of disorders such as obesity, insulin resistance, cardiovascular disease, and cancer. Deregulated expression and malfunction of FABPs can result from genetic alterations or posttranslational modifications and can be pathogenic. We have assembled the disorders with abnormal FABPs as chaperonopathies in a distinct nosological entity. This entity is similar but separate from that encompassing the chaperonopathies pertaining to protein chaperones. In this review, we discuss the role of FABPs in the pathogenesis of metabolic syndrome, cancer, and neurological diseases. We highlight the opportunities for improving diagnosis and treatment that open by encompassing all these pathological conditions within of a coherent nosological group, focusing on abnormal lipid chaperones as biomarkers of disease and etiological-pathogenic factors. |
format | Online Article Text |
id | pubmed-7591661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-75916612020-11-10 Lipid chaperones and associated diseases: a group of chaperonopathies defining a new nosological entity with implications for medical research and practice D’Anneo, Antonella Bavisotto, Celeste Caruso Gammazza, Antonella Marino Paladino, Letizia Carlisi, Daniela Cappello, Francesco de Macario, Everly Conway Macario, Alberto J. L. Lauricella, Marianna Cell Stress Chaperones Perspective and Reflection Article Fatty acid–binding proteins (FABPs) are lipid chaperones assisting in the trafficking of long-chain fatty acids with functions in various cell compartments, including oxidation, signaling, gene-transcription regulation, and storage. The various known FABP isoforms display distinctive tissue distribution, but some are active in more than one tissue. Quantitative and/or qualitative changes of FABPs are associated with pathological conditions. Increased circulating levels of FABPs are biomarkers of disorders such as obesity, insulin resistance, cardiovascular disease, and cancer. Deregulated expression and malfunction of FABPs can result from genetic alterations or posttranslational modifications and can be pathogenic. We have assembled the disorders with abnormal FABPs as chaperonopathies in a distinct nosological entity. This entity is similar but separate from that encompassing the chaperonopathies pertaining to protein chaperones. In this review, we discuss the role of FABPs in the pathogenesis of metabolic syndrome, cancer, and neurological diseases. We highlight the opportunities for improving diagnosis and treatment that open by encompassing all these pathological conditions within of a coherent nosological group, focusing on abnormal lipid chaperones as biomarkers of disease and etiological-pathogenic factors. Springer Netherlands 2020-08-27 2020-11 /pmc/articles/PMC7591661/ /pubmed/32856199 http://dx.doi.org/10.1007/s12192-020-01153-6 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Perspective and Reflection Article D’Anneo, Antonella Bavisotto, Celeste Caruso Gammazza, Antonella Marino Paladino, Letizia Carlisi, Daniela Cappello, Francesco de Macario, Everly Conway Macario, Alberto J. L. Lauricella, Marianna Lipid chaperones and associated diseases: a group of chaperonopathies defining a new nosological entity with implications for medical research and practice |
title | Lipid chaperones and associated diseases: a group of chaperonopathies defining a new nosological entity with implications for medical research and practice |
title_full | Lipid chaperones and associated diseases: a group of chaperonopathies defining a new nosological entity with implications for medical research and practice |
title_fullStr | Lipid chaperones and associated diseases: a group of chaperonopathies defining a new nosological entity with implications for medical research and practice |
title_full_unstemmed | Lipid chaperones and associated diseases: a group of chaperonopathies defining a new nosological entity with implications for medical research and practice |
title_short | Lipid chaperones and associated diseases: a group of chaperonopathies defining a new nosological entity with implications for medical research and practice |
title_sort | lipid chaperones and associated diseases: a group of chaperonopathies defining a new nosological entity with implications for medical research and practice |
topic | Perspective and Reflection Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7591661/ https://www.ncbi.nlm.nih.gov/pubmed/32856199 http://dx.doi.org/10.1007/s12192-020-01153-6 |
work_keys_str_mv | AT danneoantonella lipidchaperonesandassociateddiseasesagroupofchaperonopathiesdefininganewnosologicalentitywithimplicationsformedicalresearchandpractice AT bavisottocelestecaruso lipidchaperonesandassociateddiseasesagroupofchaperonopathiesdefininganewnosologicalentitywithimplicationsformedicalresearchandpractice AT gammazzaantonellamarino lipidchaperonesandassociateddiseasesagroupofchaperonopathiesdefininganewnosologicalentitywithimplicationsformedicalresearchandpractice AT paladinoletizia lipidchaperonesandassociateddiseasesagroupofchaperonopathiesdefininganewnosologicalentitywithimplicationsformedicalresearchandpractice AT carlisidaniela lipidchaperonesandassociateddiseasesagroupofchaperonopathiesdefininganewnosologicalentitywithimplicationsformedicalresearchandpractice AT cappellofrancesco lipidchaperonesandassociateddiseasesagroupofchaperonopathiesdefininganewnosologicalentitywithimplicationsformedicalresearchandpractice AT demacarioeverlyconway lipidchaperonesandassociateddiseasesagroupofchaperonopathiesdefininganewnosologicalentitywithimplicationsformedicalresearchandpractice AT macarioalbertojl lipidchaperonesandassociateddiseasesagroupofchaperonopathiesdefininganewnosologicalentitywithimplicationsformedicalresearchandpractice AT lauricellamarianna lipidchaperonesandassociateddiseasesagroupofchaperonopathiesdefininganewnosologicalentitywithimplicationsformedicalresearchandpractice |